A Phase I Study of Triapine [OCX 0191] in Combination With High Dose Ara-C (Hi-DAC) in Patients With Advanced Hematologic Malignancies

Trial Profile

A Phase I Study of Triapine [OCX 0191] in Combination With High Dose Ara-C (Hi-DAC) in Patients With Advanced Hematologic Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2013

At a glance

  • Drugs OCX 191 (Primary) ; Cytarabine
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Jul 2008 Completion date identified as Jul 2008, as reported by ClinicalTrials.gov.
    • 15 Jul 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
    • 09 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top